Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biogen/Ionis’s Spinraza Approved; Second Antisense Drug For Neurodegeneration In 2016

Executive Summary

Analysts expect strong uptake for the antisense oligonucleotide (ASO) given the high unmet need in SMA and positive data in multiple studies, while the first ASO approved this year – Sarepta’s Exondys 51 – has seen some pushback from payers despite the lack of DMD therapies.

Advertisement

Related Content

Biogen’s Spinraza Needs Long-Term Confirmatory Data, Says EMA
Biogen Staying "Laser-Focused" On Neuroscience
Biogen Builds In Neurodegenerative Disease With Anti-Tau Deal
Keeping Track: US FDA Approves Spinraza And Rubraca, Delays Ocrevus; Plus Submissions Galore
Biogen CEO Pick Vounatsos Suggests A Return To Commercial Focus
Biogen/Ionis’ Spinraza Data Shows Opportunity For Broad SMA Label
Anthem Denies Coverage For Eteplirsen, Citing Lack Of Clinical Efficacy
Sarepta Must Balance Exondys 51 Confirmatory Trials And Sales
Filings Soon As Biogen Snaps Up Ionis' Antisense Treatment
AbbVie/United Therapeutics $350m Voucher Deal: Smart Move?

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC097940

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel